Falcetta, Pierpaolo
Nicolì, Francesca
Citro, Fabrizia
Ciccarone, Annamaria
Garofolo, Monia
Del Prato, Stefano
Bianchi, Cristina http://orcid.org/0000-0003-2799-2380
Article History
Received: 9 August 2022
Accepted: 12 September 2022
First Online: 27 September 2022
Declarations
:
: PF, FN, FC, AC reports no duality of interest. MG reports consulting fees from Lilly. SDP declares grants from AstraZeneca and Boehringer Ingelheim, consulting fees from Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharpe and Dohme, Novartis Pharmaceuticals, Novo Nordisk and Sanofi, and honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Merck Sharpe and Dohme, Novartis Pharmaceuticals, Novo Nordisk and Sanofi. CB reports consulting fees and grants from Lilly, Novo Nordisk, Roche Diagnostics.
: The study protocol was approved by the local Ethics Committee of the University of Pisa and conducted in accordance with the Declaration of Helsinki. Since data were anonymous and used in aggregated form no subjects’ informed consent was needed according to local ethic committee indications.